ARS Pharmaceuticals, Inc.
SPRY
$9.72
-$0.08-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.72M | 7.97M | 86.58M | 2.07M | 500.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.72M | 7.97M | 86.58M | 2.07M | 500.00K |
| Cost of Revenue | 9.02M | 4.05M | 3.89M | 4.54M | 6.90M |
| Gross Profit | 6.70M | 3.93M | 82.69M | -2.47M | -6.40M |
| SG&A Expenses | 54.31M | 41.10M | 35.49M | 19.28M | 8.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.33M | 45.15M | 39.38M | 23.82M | 15.84M |
| Operating Income | -47.61M | -37.18M | 47.20M | -21.75M | -15.34M |
| Income Before Tax | -44.88M | -33.94M | 50.22M | -19.13M | -12.52M |
| Income Tax Expenses | -- | -- | 288.00K | -- | -- |
| Earnings from Continuing Operations | -44.88M | -33.94M | 49.93M | -19.13M | -12.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.88M | -33.94M | 49.93M | -19.13M | -12.52M |
| EBIT | -47.61M | -37.18M | 47.20M | -21.75M | -15.34M |
| EBITDA | -47.34M | -36.90M | 47.23M | -21.73M | -15.32M |
| EPS Basic | -0.46 | -0.35 | 0.51 | -0.20 | -0.13 |
| Normalized Basic EPS | -0.29 | -0.23 | 0.31 | -0.12 | -0.08 |
| EPS Diluted | -0.46 | -0.35 | 0.42 | -0.20 | -0.13 |
| Normalized Diluted EPS | -0.29 | -0.23 | 0.26 | -0.12 | -0.08 |
| Average Basic Shares Outstanding | 98.36M | 98.06M | 97.40M | 97.03M | 96.83M |
| Average Diluted Shares Outstanding | 98.36M | 98.06M | 119.21M | 97.03M | 96.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |